T. Rowe Price Associates
UTMD icon

T. Rowe Price Associates’s Utah Medical Products UTMD Stock Holding History

T. Rowe Price Associates’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Buy
18,300
+3,620
+25% +$228K ﹤0.01% 2093
2025
Q4 		$823K Sell
14,680
-1,484
-9% -$86K ﹤0.01% 2162
2025
Q3 		$1.02M Buy
16,164
+46
+0.3% +$2.72K ﹤0.01% 2059
2025
Q2 		$918K Buy
16,118
+648
+4% +$35.2K ﹤0.01% 2019
2025
Q1 		$868K Buy
15,470
+257
+2% +$15.4K ﹤0.01% 2028
2024
Q4 		$936K Sell
15,213
-7,227
-32% -$467K ﹤0.01% 2000
2024
Q3 		$1.5M Sell
22,440
-1,501
-6% -$102K ﹤0.01% 1776
2024
Q2 		$1.6M Buy
23,941
+1,000
+4% +$68.1K ﹤0.01% 1674
2024
Q1 		$1.63M Buy
22,941
+947
+4% +$71K ﹤0.01% 1677
2023
Q4 		$1.85M Sell
21,994
-1,979
-8% -$164K ﹤0.01% 1575
2023
Q3 		$2.06M Buy
23,973
+857
+4% +$79.1K ﹤0.01% 1450
2023
Q2 		$2.16M Buy
23,116
+56
+0.2% +$5.28K ﹤0.01% 1448
2023
Q1 		$2.19M Buy
23,060
+22
+0.1% +$2.02K ﹤0.01% 1433
2022
Q4 		$2.32M Buy
23,038
+73
+0.3% +$6.66K ﹤0.01% 1416
2022
Q3 		$1.96M Sell
22,965
-341,547
-94% -$30.1M ﹤0.01% 1463
2022
Q2 		$31.3M Sell
364,512
-700
-0.2% -$59.7K ﹤0.01% 1033
2022
Q1 		$32.8M Buy
365,212
+22,537
+7% +$2.07M ﹤0.01% 1097
2021
Q4 		$34.3M Buy
342,675
+61,290
+22% +$6.25M ﹤0.01% 1132
2021
Q3 		$26.1M Sell
281,385
-245
-0.1% -$21.6K ﹤0.01% 1229
2021
Q2 		$23.9M Buy
281,630
+1,735
+0.6% +$150K ﹤0.01% 1256
2021
Q1 		$24.2M Sell
279,895
-233
-0.1% -$20.5K ﹤0.01% 1228
2020
Q4 		$23.6M Sell
280,128
-19
-0% -$1.62K ﹤0.01% 1181
2020
Q3 		$22.4M Sell
280,147
-13,360
-5% -$1.11M ﹤0.01% 1124
2020
Q2 		$26M Sell
293,507
-5,115
-2% -$459K ﹤0.01% 1064
2020
Q1 		$28.1M Sell
298,622
-20,061
-6% -$1.86M ﹤0.01% 960
2019
Q4 		$34.4M Sell
318,683
-7,874
-2% -$798K ﹤0.01% 1030
2019
Q3 		$31.3M Buy
326,557
+893
+0.3% +$83K ﹤0.01% 1020
2019
Q2 		$31.2M Buy
325,664
+9,510
+3% +$801K ﹤0.01% 1035
2019
Q1 		$27.9M Buy
316,154
+23,562
+8% +$2.07M ﹤0.01% 1071
2018
Q4 		$24.3M Buy
292,592
+947
+0.3% +$83.4K ﹤0.01% 1087
2018
Q3 		$27.5M Buy
291,645
+61
+0% +$5.83K ﹤0.01% 1114
2018
Q2 		$32.1M Buy
291,584
+1,913
+0.7% +$200K ﹤0.01% 1043
2018
Q1 		$28.6M Buy
289,671
+109
+0% +$9.72K ﹤0.01% 1059
2017
Q4 		$23.6M Sell
289,562
-8,996
-3% -$702K ﹤0.01% 1135
2017
Q3 		$22M Sell
298,558
-4,400
-1% -$316K ﹤0.01% 1147
2017
Q2 		$21.9M Buy
302,958
+1,100
+0.4% +$72.4K ﹤0.01% 1142
2017
Q1 		$18.8M Sell
301,858
-3,161
-1% -$199K ﹤0.01% 1186
2016
Q4 		$22.2M Hold
305,019
– – ﹤0.01% 1107
2016
Q3 		$18.2M Buy
305,019
+219
+0.1% +$13.9K ﹤0.01% 1167
2016
Q2 		$19.2M Buy
304,800
+600
+0.2% +$38.7K ﹤0.01% 1116
2016
Q1 		$19M Buy
304,200
+900
+0.3% +$53.1K ﹤0.01% 1097
2015
Q4 		$17.8M Sell
303,300
-16,140
-5% -$915K ﹤0.01% 1122
2015
Q3 		$17.2M Buy
319,440
+600
+0.2% +$32.7K ﹤0.01% 1143
2015
Q2 		$19M Buy
318,840
+450
+0.1% +$25.3K ﹤0.01% 1154
2015
Q1 		$19.1M Buy
318,390
+850
+0.3% +$50K ﹤0.01% 1147
2014
Q4 		$19.1M Buy
317,540
+100
+0% +$5.54K ﹤0.01% 1126
2014
Q3 		$15.5M Buy
317,440
+250
+0.1% +$12.7K ﹤0.01% 1184
2014
Q2 		$16.3M Buy
317,190
+31,787
+11% +$1.63M ﹤0.01% 1172
2014
Q1 		$16.5M Buy
285,403
+5,247
+2% +$286K ﹤0.01% 1167
2013
Q4 		$16M Buy
280,156
+37,414
+15% +$2.05M ﹤0.01% 1156
2013
Q3 		$14.4M Buy
242,742
+28,926
+14% +$1.58M ﹤0.01% 1172
2013
Q2 		$11.6M Buy
+213,816
New +$10.1M ﹤0.01% 1207

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's UTMD Position: Q1 2026 in Review

T. Rowe Price Associates increased its Utah Medical Products (UTMD) stake by 25% in Q1 2026, buying an estimated $228K and bringing the position to 18,300 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

T. Rowe Price Associates first reported a position in UTMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $34.4M in Q4 2019. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • T. Rowe Price Associates held 18,300 shares of Utah Medical Products worth $1.14M as of Q1 2026.
  • T. Rowe Price Associates bought 3,620 Utah Medical Products shares in Q1 2026, an estimated $228K.
  • Utah Medical Products made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2093 holding.
  • T. Rowe Price Associates first reported a position in Utah Medical Products in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Utah Medical Products position peaked at $34.4M in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.